Carla Geneve

Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A

Retrieved on: 
Monday, November 6, 2023
Gene editing, Carla Geneve, Haemophilia, Therapy, RNA, Megat Burhainuddin, Novo Nordisk, Exercise, Gene, LNP, Vaccine

VANCOUVER, British Columbia, and BASEL, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A. Genevant’s collaboration with Novo Nordisk builds upon a joint research and development collaboration in hemophilia A between Novo Nordisk and 2seventy bio previously announced by 2seventy bio.

Key Points: 
  • VANCOUVER, British Columbia, and BASEL, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A. Genevant’s collaboration with Novo Nordisk builds upon a joint research and development collaboration in hemophilia A between Novo Nordisk and 2seventy bio previously announced by 2seventy bio.
  • “We are thrilled to work with Novo Nordisk in the development of a potentially transformative gene editing treatment for a patient population in need of novel therapeutic approaches,” said Pete Lutwyche, Ph.D., President and Chief Executive Officer of Genevant Sciences.
  • The agreement announced today arises from the exercise of an option under a prior agreement between Genevant and 2seventy bio and subsequently assigned by 2seventy bio to Novo Nordisk.
  • The financial terms of the agreement are in accordance with the option agreement negotiated between Genevant and 2seventy bio and as announced by 2seventy bio in January 2022.

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

Retrieved on: 
Wednesday, November 30, 2022
BioNTech, United Kingdom, Hoffmann-La Roche, RVU, Saskatchewan River Sturgeon Management Board, European, Acute myeloid leukemia, EC, Advertising, Lymphatic system, Infection, Regeneron Pharmaceuticals, Prospectus, Carla Geneve, Warsaw Stock Exchange, Drug discovery, Autoimmune disease, DNA, Myelodysplastic syndrome, RNA transfection, Research, Form, Immunity, Immunotherapy, Acquisition, AACR, Haplotype, BNTX, Knowledge, Council, Cancer, SITC, European Parliament, Pharmaceutical industry, Vaccine, Medical device, Audit, Pfizer, EU, Genentech

The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.

Key Points: 
  • The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.
  • BioNTech has the option to license global development and commercialization rights to these programs at the development candidate stage.
  • The collaboration with Ryvu provides us with the opportunity to complement our immunotherapy pipeline with a portfolio of potent immunomodulatory molecules.
  • BioNTech will fund all discovery, research and development activities, including Ryvus discovery and research activities under the multi-target research collaboration.

BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility

Retrieved on: 
Friday, October 7, 2022
BNTX, Hoffmann-La Roche, BioNTech, RNA transfection, Carla Geneve, SEC, Laboratory, Vaccine, COO, Patient, State Library Victoria, Research, RNA, Nasdaq, Partnership, Cancer, Technology, R, Infection, Private Securities Litigation Reform Act, Company, CEO, Form, Nature, Immunotherapy, Safety, State, Intention, Letter, Solution, Regeneron Pharmaceuticals, Public health, Pharmaceutical industry, Pfizer, Genentech

As part of the partnership, the parties will establish a research and innovation center in Melbourne to facilitate the transition of encouraging academic research into clinical development.

Key Points: 
  • As part of the partnership, the parties will establish a research and innovation center in Melbourne to facilitate the transition of encouraging academic research into clinical development.
  • Part of BioNTechs global network, the facility is expected to attract interest from researchers locally, regionally and globally.
  • BioNTech will support the R&D efforts on a project-by-project basis with the Companys expertise in mRNA research and clinical development of potential new products.
  • In addition to driving innovative translational research, BioNTech will also support local delivery by developing and commissioning an end-to-end clinical-scale manufacturing facility for mRNA-based medicines and product candidates in Melbourne, Victoria.

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

Retrieved on: 
Monday, February 28, 2022
GLOBE, Therapy, RNA transfection, Patent, Method, Coronavirus, Risk, Securities Exchange Act of 1934, RNA, Hepatitis B virus, IPR, United States Court of Appeals for the Federal Circuit, Immune system, Annual report, District, Carla Geneve, COVID-19, HBV, PD, Virology, Sale, LNP, MRNA-1273, MRNA, Douglas v. U.S. District Court ex rel Talk America, Complaint, Travel, District court, Severe acute respiratory syndrome coronavirus 2, RNA interference, Securities Act of 1933, Nasdaq, Forward-looking statement, Drug discovery, Patient, Technology, CEO, Program, Degenerative disease, Vaccine, Pharmaceutical industry, Security (finance), Moderna, Arbutus

William Collier, President and CEO of Arbutus, stated, Arbutus and its licensee Genevant do not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273.

Key Points: 
  • William Collier, President and CEO of Arbutus, stated, Arbutus and its licensee Genevant do not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273.
  • Scientists at Arbutus and Genevant have spent years developing and refining lipid nanoparticle (LNP) delivery technology, which has been licensed for various applications to many different third parties.
  • Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.
  • Forward-looking statements in this press release include statements about the patent infringement lawsuit against Moderna and our future development plans for our product candidates.

Acura NSX auction drives the largest ever, one-time donation for Make-A-Wish® Canada

Retrieved on: 
Thursday, February 3, 2022
VIN, Assistant, Type S, NSX, SUV, TLX, Carla Geneve, Technology, COVID-19, Honda Canada Inc., ILX, Child, Interim, RDX, Auction, Toy, Acura

TORONTO, Feb. 3, 2022 /CNW/ -Acura Canada and Make-A-WishCanada announced today that a recent online private auction of a 2022 Acura NSX Type S has led to a donation of $306,364.90, the largest, one-time, single donation the organization has received from a living donor.

Key Points: 
  • TORONTO, Feb. 3, 2022 /CNW/ -Acura Canada and Make-A-WishCanada announced today that a recent online private auction of a 2022 Acura NSX Type S has led to a donation of $306,364.90, the largest, one-time, single donation the organization has received from a living donor.
  • The auction winners, Luc Girard and Genevive Hardy were aware the proceeds were destined for Make-A-Wish Canada, a long-time partner of the Honda Canada Foundation.
  • The donation plan took root in 2021 when members of the Acura Canada team decided to auction a 2022 NSX Type S the company's limited-edition supercar.
  • Acura launched its next-generation, electrified NSX supercar as a new and pinnacle expression of Acura Precision Crafted Performance.

2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach

Retrieved on: 
Thursday, January 6, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Haemophilia A, Blood, Organic acid, Vaccine, Megat Burhainuddin, Liver, RNA transfection, Vivo, Gene editing, Translation, Haemophilia, Research, Patient, LNP, DNA, Obesity, Goal, HES, Social media, Compte rendu, Bluebird bio, U.S. Securities and Exchange Commission, Twitter, Security (finance), Disease, Diabetes, TAL, NASDAQ, LinkedIn, Conditional sentence, FDA, Partnership, Genome, RNA, Sale, TIME, Multiple myeloma, Novo Nordisk, YouTube, Technology, Risk, CAR, Novo, Lists of diseases, Factor VIII, Pharmaceutical industry, Video game console, Carla Geneve, Facebook

2seventy bio, Inc. (NASDAQ:TSVT) today announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A.

Key Points: 
  • 2seventy bio, Inc. (NASDAQ:TSVT) today announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A.
  • We are also excited to announce a partnership between 2seventy bio and Genevant Sciences for the use of Genevants lipid nanoparticle (LNP) platform in our collaboration with Novo Nordisk.
  • The collaboration agreement with Novo Nordisk builds upon the original research collaboration signed between bluebird bio and Novo Nordisk in 2019, focused on identifying a development gene therapy candidate for people with hemophilia A.
  • Under the terms of the agreement, Novo Nordisk will obtain the option to exclusively license 2seventy bios in vivo mRNA platform and gene editing technology for use in the treatment of patients with hemophilia A.

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

Retrieved on: 
Wednesday, January 5, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Severe cognitive impairment, Vaccine, COVID-19, RNA transfection, Cancer, Medicine, Infection, U.S. Securities and Exchange Commission, Twitter, Paralysis, Annual report, Carla Geneve, Disease, SEC, Technology, Shingles, News, Varicella zoster virus, Research, Hoffmann-La Roche, Science, Inc., Private Securities Litigation Reform Act, Regeneron Pharmaceuticals, BioNTech, Nasdaq, Facebook, Deafness, Clinical trial, Safety, Herpes simplex, Development, BNTX, Company, Patient, Life, Ageing, CEO, PHN, Entrepreneurship, Immunotherapy, Risk, Elanco, VZV, HZV, NYSE, Chickenpox, Postherpetic neuralgia, PFE, LinkedIn, YouTube, Multimedia, Pharmaceutical industry, Pfizer, Genentech, Shingles (Herpes Zoster Virus), Pfizer: Breakthroughs That Change Patients’ Lives, BioNTech, SHINGLES (HERPES ZOSTER VIRUS), PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES, BIONTECH

The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.

Key Points: 
  • The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.
  • This is the third collaboration between Pfizer and BioNTech in the infectious diseases field, following the influenza vaccine collaboration initiated in 2018 and the COVID-19 vaccine collaboration initiated in 2020.
  • Pfizer will have rights to commercialize the potential vaccine on a global basis, with the exception of Germany, Turkey and certain developing countries where BioNTech will have commercialization rights.
  • The collaboration aims to develop a new mRNA-based vaccine against shingles, leveraging the expertise and resources of both companies, said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech.

Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases

Retrieved on: 
Monday, August 23, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Cirrhosis, Carla Geneve, Therapy, Hepatic stellate cell, Research, RNA, Gene editing, Gastroenterology, Institute of Liver and Biliary Sciences, Takeda Pharmaceutical Company, Patient, Organic acid, Vaccine, History, LNP, Drug development

This is the second collaboration between Genevant and Takeda, following an earlier 2021 agreement to develop nucleic acid therapeutics directed to specified targets in hepatic stellate cells to treat liver fibrosis.

Key Points: 
  • This is the second collaboration between Genevant and Takeda, following an earlier 2021 agreement to develop nucleic acid therapeutics directed to specified targets in hepatic stellate cells to treat liver fibrosis.
  • LNP provides a compelling approach to deliver on the promise of gene therapy, and our leadership position in the LNP space is well established.
  • Building on our existing foundation with Genevant in liver fibrosis, were excited to expand our work together to develop life-altering, nonviral gene therapies for specified rare liver diseases, said Bernard Allan, head of liver disease research at Takeda.
  • Takeda has exclusive rights to utilize Genevants LNP technology in the development and commercialization of specified nonviral gene therapies for up to two undisclosed rare liver diseases.